326 related articles for article (PubMed ID: 30972500)
41. Analysis of Histomorphologic/Molecular Association and Immune Checkpoint Regulators in Epithelioid Glioblastoma and Pleomorphic Xanthoastrocytoma: Are These Tumors Potential Candidates for Immune Checkpoint Blockade?
Mahajan S; Singh J; Dandapath I; Jha P; Chaturvedi S; Ahuja A; Bhardwaj M; Saran R; Garg A; Sharma MC; Manjunath N; Suri A; Sarkar C; Suri V
Appl Immunohistochem Mol Morphol; 2024 Feb; 32(2):84-95. PubMed ID: 38158760
[TBL] [Abstract][Full Text] [Related]
42. Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas.
Schiffman JD; Hodgson JG; VandenBerg SR; Flaherty P; Polley MY; Yu M; Fisher PG; Rowitch DH; Ford JM; Berger MS; Ji H; Gutmann DH; James CD
Cancer Res; 2010 Jan; 70(2):512-9. PubMed ID: 20068183
[TBL] [Abstract][Full Text] [Related]
43. A case of osteoclast-like giant cell-rich epithelioid glioblastoma with BRAF V600E mutation.
Funata N; Nobusawa S; Yamada R; Shinoura N
Brain Tumor Pathol; 2016 Jan; 33(1):57-62. PubMed ID: 26602910
[TBL] [Abstract][Full Text] [Related]
44. Pleomorphic Xanthoastrocytoma: Natural History and Long-Term Follow-Up.
Ida CM; Rodriguez FJ; Burger PC; Caron AA; Jenkins SM; Spears GM; Aranguren DL; Lachance DH; Giannini C
Brain Pathol; 2015 Sep; 25(5):575-86. PubMed ID: 25318587
[TBL] [Abstract][Full Text] [Related]
45. BRAF V600E-mutated diffuse glioma in an adult patient: a case report and review.
Suzuki Y; Takahashi-Fujigasaki J; Akasaki Y; Matsushima S; Mori R; Karagiozov K; Joki T; Ikeuchi S; Ikegami M; Manome Y; Murayama Y
Brain Tumor Pathol; 2016 Jan; 33(1):40-9. PubMed ID: 26445861
[TBL] [Abstract][Full Text] [Related]
46. BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma.
Mistry M; Zhukova N; Merico D; Rakopoulos P; Krishnatry R; Shago M; Stavropoulos J; Alon N; Pole JD; Ray PN; Navickiene V; Mangerel J; Remke M; Buczkowicz P; Ramaswamy V; Guerreiro Stucklin A; Li M; Young EJ; Zhang C; Castelo-Branco P; Bakry D; Laughlin S; Shlien A; Chan J; Ligon KL; Rutka JT; Dirks PB; Taylor MD; Greenberg M; Malkin D; Huang A; Bouffet E; Hawkins CE; Tabori U
J Clin Oncol; 2015 Mar; 33(9):1015-22. PubMed ID: 25667294
[TBL] [Abstract][Full Text] [Related]
47. Granular cell astrocytoma: an aggressive IDH-wildtype diffuse glioma with molecular genetic features of primary glioblastoma.
Vizcaino MA; Palsgrove DN; Yuan M; Giannini C; Cabrera-Aldana EE; Pallavajjala A; Burger PC; Rodriguez FJ
Brain Pathol; 2019 Mar; 29(2):193-204. PubMed ID: 30222900
[TBL] [Abstract][Full Text] [Related]
48. Genetic alterations commonly found in diffusely infiltrating cerebral gliomas are rare or absent in pleomorphic xanthoastrocytomas.
Kaulich K; Blaschke B; Nümann A; von Deimling A; Wiestler OD; Weber RG; Reifenberger G
J Neuropathol Exp Neurol; 2002 Dec; 61(12):1092-9. PubMed ID: 12484572
[TBL] [Abstract][Full Text] [Related]
49. Glioblastoma in neurofibromatosis 1 patients without IDH1, BRAF V600E, and TERT promoter mutations.
Shibahara I; Sonoda Y; Suzuki H; Mayama A; Kanamori M; Saito R; Suzuki Y; Mashiyama S; Uenohara H; Watanabe M; Kumabe T; Tominaga T
Brain Tumor Pathol; 2018 Jan; 35(1):10-18. PubMed ID: 29138945
[TBL] [Abstract][Full Text] [Related]
50. Genetic aberrations leading to MAPK pathway activation mediate oncogene-induced senescence in sporadic pilocytic astrocytomas.
Jacob K; Quang-Khuong DA; Jones DT; Witt H; Lambert S; Albrecht S; Witt O; Vezina C; Shirinian M; Faury D; Garami M; Hauser P; Klekner A; Bognar L; Farmer JP; Montes JL; Atkinson J; Hawkins C; Korshunov A; Collins VP; Pfister SM; Tabori U; Jabado N
Clin Cancer Res; 2011 Jul; 17(14):4650-60. PubMed ID: 21610151
[TBL] [Abstract][Full Text] [Related]
51. BRAF V600E mutation and 9p21: CDKN2A/B and MTAP co-deletions - Markers in the clinical stratification of pediatric gliomas.
Frazão L; do Carmo Martins M; Nunes VM; Pimentel J; Faria C; Miguéns J; Sagarribay A; Matos M; Salgado D; Nunes S; Mafra M; Roque L
BMC Cancer; 2018 Dec; 18(1):1259. PubMed ID: 30558563
[TBL] [Abstract][Full Text] [Related]
52. Genetic Analysis of Diffuse High-Grade Astrocytomas in Infancy Defines a Novel Molecular Entity.
Gielen GH; Gessi M; Buttarelli FR; Baldi C; Hammes J; zur Muehlen A; Doerner E; Denkhaus D; Warmuth-Metz M; Giangaspero F; Lauriola L; von Bueren AO; Kramm CM; Waha A; Pietsch T
Brain Pathol; 2015 Jul; 25(4):409-17. PubMed ID: 25231549
[TBL] [Abstract][Full Text] [Related]
53. Epithelioid GBMs show a high percentage of BRAF V600E mutation.
Kleinschmidt-DeMasters BK; Aisner DL; Birks DK; Foreman NK
Am J Surg Pathol; 2013 May; 37(5):685-98. PubMed ID: 23552385
[TBL] [Abstract][Full Text] [Related]
54. Targeted therapy for BRAFV600E malignant astrocytoma.
Nicolaides TP; Li H; Solomon DA; Hariono S; Hashizume R; Barkovich K; Baker SJ; Paugh BS; Jones C; Forshew T; Hindley GF; Hodgson JG; Kim JS; Rowitch DH; Weiss WA; Waldman TA; James CD
Clin Cancer Res; 2011 Dec; 17(24):7595-604. PubMed ID: 22038996
[TBL] [Abstract][Full Text] [Related]
55. Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status.
Thompson EM; Landi D; Ashley D; Keir ST; Bigner D
J Neurooncol; 2018 Nov; 140(2):261-268. PubMed ID: 30120661
[TBL] [Abstract][Full Text] [Related]
56. pRB immunostaining in the differential diagnosis between pleomorphic xanthoastrocytoma and glioblastoma with giant cells.
Barresi V; Simbolo M; Ciaparrone C; Pedron S; Mafficini A; Scarpa A
Histopathology; 2022 Nov; 81(5):661-669. PubMed ID: 35945679
[TBL] [Abstract][Full Text] [Related]
57. Malignant transformation of pleomorphic xanthoastrocytoma and differential diagnosis: case report.
Watanabe N; Ishikawa E; Kohzuki H; Sakamoto N; Zaboronok A; Matsuda M; Shibuya M; Matsumura A
BMC Neurol; 2020 Jan; 20(1):21. PubMed ID: 31941461
[TBL] [Abstract][Full Text] [Related]
58. Epithelioid Glioblastomas and Anaplastic Epithelioid Pleomorphic Xanthoastrocytomas--Same Entity or First Cousins?
Alexandrescu S; Korshunov A; Lai SH; Dabiri S; Patil S; Li R; Shih CS; Bonnin JM; Baker JA; Du E; Scharnhorst DW; Samuel D; Ellison DW; Perry A
Brain Pathol; 2016 Mar; 26(2):215-23. PubMed ID: 26238627
[TBL] [Abstract][Full Text] [Related]
59. Establishment and characterization of patient-derived xenograft of a rare pediatric anaplastic pleomorphic xanthoastrocytoma (PXA) bearing a CDC42SE2-BRAF fusion.
Damayanti NP; Saadatzadeh MR; Dobrota E; Ordaz JD; Bailey BJ; Pandya PH; Bijangi-Vishehsaraei K; Shannon HE; Alfonso A; Coy K; Trowbridge M; Sinn AL; Zhang ZY; Gallagher RI; Wulfkuhle J; Petricoin E; Richardson AM; Marshall MS; Lion A; Ferguson MJ; Balsara KE; Pollok KE
Sci Rep; 2023 Jun; 13(1):9163. PubMed ID: 37280243
[TBL] [Abstract][Full Text] [Related]
60. Biomarker-driven diagnosis of diffuse gliomas.
Appin CL; Brat DJ
Mol Aspects Med; 2015 Nov; 45():87-96. PubMed ID: 26004297
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]